Daniel Lippis Sells 619 Shares of Edwards Lifesciences (NYSE:EW) Stock

Edwards Lifesciences Corporation (NYSE:EW) VP Daniel Lippis sold 619 shares of Edwards Lifesciences stock in a transaction that occurred on Friday, July 10th. The shares were sold at an average price of $91.70, for a total transaction of $56,762.30. Following the completion of the transaction, the vice president owned 40,034 shares of the company’s stock, valued at $3,671,117.80. This represents a 1.52% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Edwards Lifesciences Stock Performance

EW stock traded up $0.89 during midday trading on Friday, reaching $92.22. 3,381,397 shares of the company’s stock traded hands, compared to its average volume of 4,354,287. The firm has a market capitalization of $53.10 billion, a PE ratio of 49.05, a price-to-earnings-growth ratio of 2.31 and a beta of 0.86. The company has a 50-day moving average price of $86.73 and a two-hundred day moving average price of $83.87. Edwards Lifesciences Corporation has a 52 week low of $72.30 and a 52 week high of $96.29. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.63 and a current ratio of 4.42.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings results on Thursday, April 23rd. The medical research company reported $0.78 EPS for the quarter, topping analysts’ consensus estimates of $0.73 by $0.05. The firm had revenue of $1.65 billion during the quarter, compared to analyst estimates of $1.60 billion. Edwards Lifesciences had a return on equity of 15.19% and a net margin of 17.39%.The business’s revenue for the quarter was up 16.7% on a year-over-year basis. During the same period last year, the company earned $0.64 earnings per share. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. As a group, equities analysts anticipate that Edwards Lifesciences Corporation will post 3 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the business. Hanson & Doremus Investment Management purchased a new position in Edwards Lifesciences in the 1st quarter worth approximately $25,000. JPL Wealth Management LLC bought a new stake in shares of Edwards Lifesciences during the 3rd quarter worth $25,000. MV Capital Management Inc. purchased a new position in Edwards Lifesciences in the fourth quarter worth $26,000. RMG Wealth Management LLC purchased a new stake in Edwards Lifesciences during the first quarter valued at about $26,000. Finally, Kemnay Advisory Services Inc. purchased a new stake in Edwards Lifesciences during the fourth quarter valued at about $27,000. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on EW shares. Truist Financial set a $90.00 target price on Edwards Lifesciences and gave the company a “hold” rating in a report on Friday, April 24th. BTIG Research increased their price target on shares of Edwards Lifesciences from $100.00 to $110.00 and gave the stock a “buy” rating in a report on Tuesday, June 30th. Evercore restated an “outperform” rating and issued a $100.00 price objective on shares of Edwards Lifesciences in a research report on Monday, July 6th. Robert W. Baird boosted their price objective on shares of Edwards Lifesciences from $85.00 to $87.00 and gave the company a “neutral” rating in a research note on Friday, April 24th. Finally, Wall Street Zen cut shares of Edwards Lifesciences from a “buy” rating to a “hold” rating in a research note on Saturday, July 4th. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and eight have assigned a Hold rating to the company’s stock. According to MarketBeat, Edwards Lifesciences presently has a consensus rating of “Moderate Buy” and a consensus target price of $97.09.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.